Conference Menu

Day 1
Day 2
PDF Download
Short Courses
General Information 
Hotel & Travel 
Supporter & Exhibitor 
Press Pass 
Request Brochure


Future Diagnostics




SMP mini Banner 

We wish to thank the following for their educational grant in support of this activity: 

KMC Systems 

Lead Supporting Publications: 

Bio-IT World 

Genetic Engineering &
Biotechnology News



The Scientist 

Supporting Publications: 

Drug Discovery News 

Genome Technology 

INSIGHT Pharma Reports 

Pharma Voice 

Web Partners: 


Future Diagnostics - Day 2

Conference Proceeding CD Now Available
  • Speaker Presentations
  • Poster Abstracts
  • and More!

Tuesday, April 17

*Lectures are CME accredited unless otherwise noted.

7:30 am Morning Coffee


Focus on Diagnostic Applications

8:30 am Chairperson’s Opening Remarks

Abraham P. Lee, Ph.D., William J. Link Professor and Chair, Department of Biomedical Engineering; Director, Micro/Nano Fluidics Fundamentals Focus (MF3) Center, University of California, Irvine

8:35 Lateral Cavity Acoustic Transducer as an On-Chip Cell/Particle Microfluidic Switch

Abraham-LeeAbraham P. Lee, Ph.D., William J. Link Professor and Chair, Department of Biomedical Engineering; Director, Micro/Nano Fluidics Fundamentals Focus (MF3) Center, University of California, Irvine

A novel on-chip microfluidic switch is demonstrated that utilizes the acoustic microstreaming generated by an oscillating air-liquid interface to switch cells/particles into bifurcating microchannels. The air-liquid interface of the Lateral Cavity Acoustic Transducers (LCATs) can be actuated by an external acoustic energy source causing the interface to oscillate. The oscillating interface results in the generation of vortex-like microstreaming flow within a localized region of the surrounding liquid. This streaming was utilized here to deflect cells/particles into a collection outlet. It was demonstrated that the switching zone could be controlled by varying the actuation time of the LCAT. An LCAT based microfluidic switch is capable of achieving theoretical switching rates of 800 cells/particles per second. It was also demonstrated that K562 cells could be switched into a collection channel with cell viability comparable to that of controls as determined by Trypan blue exclusion assay.

9:05 Portable Microfluidic Devices for Pathogen & Biotoxin Diagnostics

Greg Sommer, Ph.D., Senior Member, Technical Staff, Biotechnology and Bioengineering Department, Sandia National Laboratories

There is an urgent need for rapid, cost-effective and sensitive diagnostic devices to detect exposure to emerging infectious agents and biotoxins. We have developed an integrated microfluidic platform that can perform rapid, sensitive and multiplexed immunoassays for detection of toxins and pathogenic bacteria. The platform requires no off-device sample preparation and its ability to perform rapid assays with minute amounts of sample makes it attractive for point-of-care applications.

9:35 Chip-Based Instruments for the Detection of Rare Cells for Diagnostic Applications
(Not CME Accredited)

Robert Proulx, General Manager, U.S. Operations, Silicon Biosystems

Although the CTC count is a valuable tool for prognostic indication, the full potential of CTC in personalized therapy is bound to their molecular profiling. However the enrichment technologies currently available provide a level of purity incompatible with the majority of molecular analyses. The DEPArray™ System overcomes this limitation by implementing an image-based single-cell sorting to deliver 100% pure cells which, following whole genome amplification, provides the key to the unravelling of their molecular profile.

10:00 Coffee Break with Exhibit & Poster Viewing


10:25 Chairperson’s Remarks

Jennifer Prescher, Ph.D., Assistant Professor, Departments of Chemistry, Molecular Biology & Biochemistry, University of California, Irvine

10:30 Addressing the Challenges of Early Cancer Detection with Micro-Optical Designs

Christopher H. Contag, Ph.D., Associate Professor, Pediatrics – Neonatology; Member, Child Health Research Institute; Member, Bio-X; Member, Cancer Center, Stanford University

Current detection of cancer lacks the sensitivity for early detection when therapy would be most effective. New instruments based on micro-optical designs can be used to reach in the body to reveal microanatomic and molecular details that indicate early cancer. Optical imaging provides molecular sensitivity and cellular level resolution that will inform diagnosis, prognosis and therapy, and guide biopsies for multiparameter analyses.

11:00 Contrast Enhanced Imaging of Disease at the Tissue, Cellular, and Molecular Level

Andrew-TsourkasAndrew Tsourkas, Ph.D., Associate Professor, Bioengineering & Radiology, University of Pennsylvania

Our lab develops contrast agents to non-invasively image molecular markers of disease in living subjects. I will discuss some of our recent advances and how we hope to use nanotechnology to improve initial cancer diagnosis and patient management.

11:30 Target-Cancer Cell Specific “Smart” Optical Imaging Probes for Super-Specific Detection and Diagnosis

Hisataka-KobayashiHisataka Kobayashi, M.D., Ph.D., Chief Scientist, Molecular Imaging Program, NCI/NIH

A major goal of in vivo targeted molecular imaging of cancer is to improve the sensitivity and specificity so that even minimal clusters of aberrant cells can be detected in vivo thus permitting earlier intervention and perfect surgery. Herein, we propose several different fluorescence-based activatable “smart” strategies of maximizing target signal while minimizing or eliminating the background signal. With these activatable imaging strategies, we have designed and synthesized a series of activatable “smart” cancer-targeting probes against various target molecules, and achieved target specific cancer imaging with extremely low background signal, while clearly depicting peritoneally disseminated micro-metastasis, de novo small colon cancers, and lung micro-metastasis with extremely high sensitivity and specificity. For the surgery assistance, we have recently designed and synthesized a “sprayable” activatable imaging probe for detecting tiny cancers based on quick activation within a minute that is feasible for the use during the procedure.

12:00 Shining Light on Pancreatic Cancer

Mary-Ann-MycekMary-Ann Mycek, Ph.D., Associate Professor, Department of Biomedical Engineering, Faculty Member, Applied Physics Program, Core Member, Comprehensive Cancer Center, University of Michigan

In the United States, pancreatic adenocarcinoma is the fourth leading cause of cancer death, with a 5-year survival rate of only 5%.  This dismal prognosis for pancreatic cancer patients is attributed mainly to the inability of current clinical methods to accurately detect the disease in its early stages of development.  Our research in Biomedical Optics develops tools to probe and quantify tissues in vivo, with a goal of impacting clinical care by creating non- and minimally-invasive optical diagnostic technologies.

12:30 Luncheon Presentation or Lunch On Own

(Support Opportunity Available)


1:30 Chairperson’s Remarks

John-KrowleskiJohn J. Krolewski, M.D., Ph.D., Professor, Pathology & Laboratory Medicine, University of California, Irvine

1:35 The Development and Approval of Xalkori for the Treatment of ALk-Rearranged Non-Small Cell Lung Cancer: A New Paradigm in the Era of Targeted Therapy in Oncology

Sai-Hong Ignatius OuSai-Hong Ignatius Ou, M.D., Ph.D., Health Science Associate Clinical Professor of Medicine, Division of Hematology-Medical Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center

It took  an astounding short 4 years from the publication of the discovery of ALK-rearranged NSCLC in August, 2007 to the conditional approval of Xalkori for the treatment of ALK-rearranged NSCLC in August, 2011. This would not have happened without the rapid development and validation of a companion diagnostic test and the close cooperation and comaraderie between the phase I investigators and the sponsor of Xalkori.

2:05 HER2 Testing Using INFORM HER2 Dual in situ Hybridization

Philip-CarpenterPhilip M. Carpenter, Associate Clinical Professor, Pathology, School of Medicine, University of California, Irvine

HER2 amplification testing for equivocal cases is currently routinely performed by fluorescence in situ hybridization, an accurate but labor intensive test requiring specific equipment. Our laboratory has performed validation and workflow optimization of HER2 testing using INFORM HER2 Dual in situ hybridization.

2:35 Personalizing Medicine: The cobas® 4800 BRAF V600 Mutation Test
(Not CME Accredited)

Sarah-Mosely Sarah Moseley, Ph.D., Principal Applications Scientist, Medical and Scientific Affairs, Roche Diagnostics

The first FDA approved companion diagnostic test for selection of metastatic melanoma patients to receive the targeted drug therapy Zelboraf™.  We will discuss the test, the impacts on the melanoma disease state and the implications for a new era in personalized medicine.

3:05 Panel Discussion with Afternoon Speakers: Development and Implementation of Novel Diagnostic Platforms from Stakeholder Perspectives
(Not CME Accredited)

•   Choosing the right product platform
•   Whether test should be reflex or ordered?
•   Reimbursement of test
•   Turnaround time
•   Access to adequate diagnostic material
•   Utilizing smaller sample size
•   Need for plasticity of platforms
•   Bringing tests to patient: off label use considerations


John-KrowleskiJohn J. Krolewski, M.D., Ph.D., Professor, Pathology & Laboratory Medicine, University of California, Irvine

Additional Panelists:

Edward Nelson, M.D., Assistant Professor, Medicine Hematology & Oncology, University of California, Irvine
William G. Loudon, M.D., Ph.D., Assistant Professor, Neurosurgery, University of California Irvine; Section Chief, Neurosurgery, Children’s Hospital of Orange County

4:00 Close of Future Diagnostics Conference

By Series:
By Region:

& Course Catalog

CHI Catalog 

Short Course DVDs